Prognostic factors for survival in patients with metastatic renal cancer treated with biological response modifiers.

No abstract is available for this paper.

• Publication year

  1995

• Venue

  Journal of Urology

• Publication date

  1995-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/S0022-5347(01)67218-5PMID 7539867
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma

  2005cited by this paper
• Erythropoietin production. A potential marker for interleukin‐2/interferon‐responsive tumors

  1993cited by this paper
• Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2.

  1992cited by this paper
• Serum level of interleukin 6 as a prognosis factor in metastatic renal cell carcinoma.

  1992cited by this paper
• The prognostic significance of immune changes in patients with renal cell carcinoma treated with interferon alfa-2b.

  1992cited by this paper
• Flow cytometric deoxyribonucleic acid analysis in stage I renal cell carcinoma.

  1991cited by this paper
• The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma.

  1991cited by this paper
• Therapeutic options in renal cell carcinoma.

  1989cited by this paper
• Therapeutic options in renal cell carcinoma.

  1989cited by this paper
• Clinical immunotherapy studies in the Surgery Branch of the U.S. National Cancer Institute: brief review.

  1989cited by this paper
• Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.

  1988cited by this paper
• Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma

  1988cited by this paper
• Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma.

  1988cited by this paper
• Renal carcinoma. Reevaluation of prognostic factors

  1988cited by this paper
• Prognostic factors of adult metastatic renal carcinoma: a multivariate analysis.

  1988cited by this paper
• Interferon therapy for renal cell carcinoma.

  1987cited by this paper
• A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

  1987cited by this paper
• Intrinsic drug resistance in human kidney cancer is associated with expression of a human multidrug-resistance gene.

  1987cited by this paper
• Sarcomatoid renal cell carcinoma. A treatable entity

  1987cited by this paper
• Phase I/II trial of human recombinant beta-interferon serine in patients with renal cell carcinoma.

  1986cited by this paper
• Prognostic factors in metastatic renal carcinoma.

  1986cited by this paper
• Phase II trial of misonidazole (MISO) and cyclophosphamide (CYC) in metastatic renal cell carcinoma.

  1986cited by this paper
• Phase I/II Trial of Human Recombinant β-Interferon Serine in Patients with Renal Cell Carcinoma

  1986cited by this paper
• A randomized study of low and high doses of leukocyte alpha-interferon in metastatic renal cell carcinoma: the American Cancer Society collaborative trial.

  1985cited by this paper
• Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

  1985cited by this paper
• Therapeutic options in renal-cell carcinoma.

  1985cited by this paper
• Human lymphoblastoid interferon therapy for advanced renal cell carcinoma.

  1984cited by this paper
• Hormonal therapy and chemotherapy of renal-cell carcinoma.

  1983cited by this paper
• Immunologic therapies of kidney carcinoma.

  1983cited by this paper
• Phase II study of PALA and AMSA in advanced renal cell carcinoma.

  1983cited by this paper
• The Statistical Analysis of Failure Time Data

  1980cited by this paper
• Phase II study of single-agent therapy with megestrol acetate, VP-16-213, cyclophosphamide, and dianhydrogalactitol in advanced renal cell cancer.

  1979cited by this paper
• The natural history of metastatic renal cell carcinoma: a computer analysis.

  1978cited by this paper
• Renal cell carcinoma: natural history and results of treatment.

  1978cited by this paper
• The value of radiotherapy in the treatment of hypernephroma--a clinical trial.

  1973cited by this paper
• An evaluation of postoperative radiotherapy in hypernephroma treatment—A clinical trial

  1973cited by this paper
• [New drugs. 6].

  1971cited by this paper
• Renal cell carcinoma. Natural history and results of treatment

  1970cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper
• Hydatid Disease

  1895cited by this paper

• Treatments for renal cell carcinoma: NICE Pilot Treatment Pathways Appraisal.

  2026cites this paper
• Efficacy of cabozantinib and sunitinib for the treatment of intermediate/poor risk renal cell carcinoma based upon UK real-world data

  2024cites this paper
• Impact of Metastasectomy on Cancer Specific and Overall Survival in Metastatic Renal Cell Carcinoma: Analysis of the REMARCC Registry.

  2022cites this paper
• Gene Expression Analysis of Aggressive Clinical T1 Stage Clear Cell Renal Cell Carcinoma for Identifying Potential Diagnostic and Prognostic Biomarkers

  2020cites this paper
• A retrospective study evaluating the pretreatment tumor volume (PTV) in non-small cell lung cancer (NSCLC) as a predictor of response to program death-1 (PD-1) inhibitors

  2019cites this paper
• Cytoreductive nephrectomy in metastatic kidney cancer: what do we do now?

  2019cites this paper
• Unified Approaches to Surgery and Systemic Therapy for Renal Cell Carcinoma

  2019cites this paper
• The use of cytoreductive nephrectomy in patients with renal cell carcinoma

  2019cites this paper
• The Japanese version of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE): psychometric validation and discordance between clinician and patient assessments of adverse events

  2018cites this paper
• Megaprosthesis for Metastasis of the Lower Limb

  2018cites this paper
• Predictors of survival after intramedullary nail fixation of completed or impending pathologic femur fractures from metastatic disease.

  2018cites this paper
• Cytoreductive nephrectomy for metastatic renal cell carcinoma.

  2016cites this paper
• Chapter 45 – Diagnosis of bone metastases in urological malignancies – an update

  2015cites this paper
• Surgical management of bone metastases from urological malignancies: an analysis of 70 cases.

  2015cites this paper
• Hypothyroidism as a predictive clinical marker of better treatment response to sunitinib therapy.

  2014cites this paper
• Prognostic factors for overall survival with targeted therapy in Chinese patients with metastatic renal cell carcinoma.

  2014cites this paper
• Limitations of selection criteria of ongoing randomized controlled trials testing targeted therapies in an adjuvant setting of patients with renal cell carcinoma

  2014cites this paper
• Immunotherapy in Renal Cell Carcinoma

  2014cites this paper
• Efficacy of targeted therapy for metastatic renal cell carcinoma in the elderly patient population.

  2014cites this paper
• Combination of zoledronic Acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma.

  2013cites this paper
• Cytoreductive nephrectomy: a treatment of the past.

  2013cites this paper
• Integration of surgery and systemic therapy for renal cell carcinoma.

  2012cites this paper
• New surgical horizons: the role of cytoreductive nephrectomy for metastatic kidney cancer.

  2012cites this paper
• Variant Renal Cell Carcinoma Histologies: Therapeutic Considerations

  2012cites this paper
• Prognostic factors for progression-free and overall survival with sunitinib targeted therapy and with cytokine as first-line therapy in patients with metastatic renal cell carcinoma.

  2011cites this paper
• Renal Cell Carcinoma

  2011cites this paper
• Boning up on prognostic factors in advanced renal cell carcinoma.

  2011cites this paper
• [Role of surgery (cytoreductive nephrectomy and metastasectomy) in the management of metastatic renal cell carcinoma: a literature review].

  2010cites this paper
• La néphrectomie est-elle indispensable en cas de métastases ?

  2010cites this paper
• Первый опыт применения таргетных препаратов при раке почки

  2010cites this paper
• Diagnosis of bone metastases in urological malignancies--an update.

  2010cites this paper
• [Is the cytoreductive nephrectomy still necessary in case of metastases?].

  2010cites this paper
• Management of metastatic renal cell carcinoma in patients with poor prognosis

  2010cites this paper
• Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy?

  2010cites this paper
• Imaging of Bone Metastases

  2010cites this paper
• Management of metastatic renal cell carcinoma in patients with poor prognosis

  2010cites this paper
• Place de la chirurgie (néphrectomie cytoréductrice et métastasectomie) dans la prise en charge du cancer du rein métastatique : revue de la littérature

  2010cites this paper
• [Critical analysis of prognostic factors for metastatic renal cell carcinoma].

  2009cites this paper
• Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy

  2009cites this paper
• Analyse critique des classifications pronostiques du cancer du rein métastatique

  2009cites this paper
• The role of cytoreductive nephrectomy in the era of molecular targeted therapy

  2009cites this paper
• Prognostic factors for survival in metastatic renal cell carcinoma

  2009cites this paper
• Interferon-&agr; in combination with either imatinib (Gleevec) or gefitinib (Iressa) in metastatic renal cell carcinoma: a phase II trial

  2008cites this paper
• Local Recurrence After Radical Nephrectomy for Renal Cell Carcinoma

  2008cites this paper
• Salvage paclitaxel chemotherapy for metastatic collecting duct carcinoma of the kidney.

  2008cites this paper
• The staging of renal cell carcinoma

  2008cites this paper
• Prognostic factors and selection for clinical studies of patients with kidney cancer.

  2008cites this paper
• Performance status and cytoreductive nephrectomy

  2008cites this paper
• Staging of Renal Cell Carcinoma

  2008cites this paper
• Nephrectomy in Patients with Metastatic Renal Cell Carcinoma: Clinical and Biologic Effects

  2008cites this paper
• Prognostic Factors for Survival in Metastatic Renal Cell Carcinoma

  2008cites this paper
• Outcome after cytoreductive nephrectomy for metastatic renal cell carcinoma is predicted by fractional percentage of tumour volume removed

  2007cites this paper
• Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation.

  2007cites this paper
• Characteristics of Metastasis as a Prognostic Factor for Immunotherapy in Metastatic Renal Cell Carcinoma

  2007cites this paper
• Survival and prognostic classification of patients with metastatic renal cell carcinoma of bone.

  2007cites this paper
• Plasma osteopontin in comparison with bone markers as an indicator of distant metastases and a predictor of survival outcome in prostate cancer and renal cell carcinoma patients

  2007cites this paper
• Serum immunosuppressive acidic protein doubling time as a prognostic factor for recurrent renal cell carcinoma after nephrectomy.

  2006cites this paper
• Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma.

  2006cites this paper
• Kombination von Immun- und Strahlentherapie für Patienten mit ossär metastasiertem Nierenzellkarzinom

  2006cites this paper
• Surgical management of renal cell carcinoma.

  2006cites this paper
• Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma.

  2006cites this paper
• Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma.

  2006cites this paper
• Prognostic factors in renal cell carcinoma.

  2006cites this paper
• [Surgical treatment and evaluation of prognostic factors in spinal metastases of renal cell carcinoma].

  2006cites this paper
• Fibrosis intersticial y carcinoma renal de células claras

  2006cites this paper
• Cytoreductive nephrectomy in metastatic renal cell carcinoma

  2006cites this paper
• Prognostic factors and the role of neprectomy in metastatic renal cell carcinoma

  2006cites this paper
• Treatment of bone metastases and local recurrence from renal cell carcinoma with immunochemotherapy and radiation

  2005cites this paper
• Survival in patients operated on for pathologic fracture: implications for end-of-life orthopedic care.

  2005cites this paper
• Vliv věku, pohlaví a ecog skóre na prognózu karcinomu ledviny

  2005cites this paper
• Lessons learned in the surgical management of renal cell carcinoma.

  2005cites this paper
• Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis.

  2005cites this paper
• Surgery for metastatic renal cell cancer

  2005cites this paper
• Multifocal metastases of recurrent renal cell carcinoma successfully treated with a combination of low dose interleukin‐2, α‐interferon and radiotherapy

  2005cites this paper
• Neural Mechanisms of Anorexia

  2004cites this paper
• Prognostic factors for survival of patients after curative surgery for renal cell carcinoma: multivariate analysis of 482 cases

  2004cites this paper
• Use of American Society of Anesthesiologists physical status classification to assess perioperative risk in patients undergoing radical nephrectomy for renal cell carcinoma.

  2004cites this paper
• Cachexia-like symptoms predict a worse prognosis in localized t1 renal cell carcinoma.

  2004cites this paper
• Metachronous Solitary Contralateral Adrenal Metastasis of Renal Cell Carcinoma: Case Report and Literature Review

  2004cites this paper
• Microscopic venous invasion in renal cell carcinoma as a predictor of recurrence after radical surgery

  2004cites this paper
• Debulking Nephrectomy in Metastatic Renal Cancer

  2004cites this paper
• Characterization of bone metastases in patients with renal cell cancer

  2004cites this paper
• Prognostic Factors in Patients with Advanced Renal Cell Carcinoma

  2004cites this paper
• Basic biology and clinical behavior of renal cell carcinoma.

  2003cites this paper
• METÁSTASIS CEREBRAL SOLITARIA DE UN CARCINOMA DE CÉLULAS RENALES

  2003cites this paper
• Renal cell carcinoma: new prognostic factors?

  2003cites this paper
• Number of metastatic sites rather than location dictates overall survival of patients with node-negative metastatic renal cell carcinoma.

  2003cites this paper
• [Solitary cerebral metastasis of a renal cell carcinoma].

  2003cites this paper
• Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma

  2003cites this paper
• Metastatic renal cell cancer treatments.

  2003cites this paper
• Cytoreductive nephrectomy in metastatic renal cancer

  2003cites this paper
• Prognostic factors of renal cell carcinoma.

  2003cites this paper
• Novel concepts in the staging of renal cell carcinoma

  2003cites this paper
• Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-α in patients with progressive metastatic renal cell carcinoma

  2003cites this paper
• Role of nephrectomy in metastatic kidney cancer.

  2003cites this paper
• Stratification by risk factors predicts survival on the active treatment arm in a randomized phase II study of interferon-gamma plus/minus interferon-alpha in advanced renal cell carcinoma (E6890)

  2003cites this paper
• Metastatic renal carcinoma comprehensive prognostic system

  2003cites this paper
• Prognostic factors of immunotherapy in metastatic renal cell carcinoma

  2003influential citation
• New algorithms for the staging of kidney cancer.

  2003cites this paper
• Scoring algorithm to predict survival after nephrectomy and immunotherapy in patients with metastatic renal cell carcinoma

  2003cites this paper